NCT06697184 - A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

Chronic Lymphocytic LeukemiaCLL

Interventions

DRUG

Sonrotoclax

Administered orally

DRUG

Zanubrutinib

Administered orally

Trial Locations (16)

21000

RECRUITING

Chu Dijon, Dijon

31100

RECRUITING

Iuct Oncopole, Toulouse

34090

RECRUITING

Chu Montpellier Hopital Saint Eloi, Montpellier

46804

RECRUITING

Fort Wayne Medical Oncology and Hematology, Fort Wayne

33612-9496

RECRUITING

Moffitt Cancer Center, Tampa

66205-2003

RECRUITING

The University of Kansas Cancer Center, Westwood

02215-5418

RECRUITING

Dana Farber Cancer Institute, Boston

63110-1010

RECRUITING

Washington University School of Medicine, St Louis

98109-4433

RECRUITING

Fred Hutchinson Cancer Research Center, Seattle

NSW 2148

RECRUITING

Blacktown Cancer and Haematology Centre, Blacktown

VIC 3144

RECRUITING

Cabrini Hospital Malvern, Malvern East

VIC 3004

RECRUITING

The Alfred Hospital, Melbourne

WA 6168

RECRUITING

Rockingham Hospital, Cooloongup

WA 6009

RECRUITING

Linear Clinical Research, Nedlands

B15 2TH

NOT_YET_RECRUITING

Queen Elizabeth Hospital, Birmingham

LS9 7TF

NOT_YET_RECRUITING

St Jamess University Hospital, Leeds